Q-omics provides the consensus-scored TMEM179B profile across patient tissues and cancer cell-line models. TMEM179B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TMEM179B is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, TMEM179B RNA expression shows 18,883 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, HNSC, and ACC as cancer lineages where TMEM179B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM179B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM179B survival associations across molecular data types. TMEM179B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM179B RNA expression–survival associations across cancer types. High TMEM179B expression shows unfavorable associations in UVM, HNSC, ACC, PAAD and LGG, but favorable associations in MESO. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TMEM179B RNA expression.
This table summarizes TMEM179B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM179B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM179B shows lower tumor expression in KICH and higher tumor expression in HNSC, BLCA, LIHC, BRCA and STAD. The HNSC box plot shows higher TMEM179B RNA expression in tumor versus normal tissue (log2 FC = +0.751, t-test p < 0.001).
This table shows molecular features associated with TMEM179B in patient tissues and cancer cell lines. In patient samples, TMEM179B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM179B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
